Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance.
Tassadit BelabbasTakaaki YamadaNobuaki EgashiraTakeshi HirotaKimitaka SuetsuguYasuo MoriKoji KatoKoichi AkashiIchiro IeiriPublished in: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2023)
AML patients with neutropenia and ARC represent a critical population with a higher risk of VCM underexposure. Thus, individualized dosing adjustment and therapeutic drug monitoring are strongly recommended.